NCT05138523View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)

CompletedOBSERVATIONAL
Enrollment

99

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

November 18, 2020

Study Completion Date

June 22, 2021

Conditions
Chronic Hepatitis c
Interventions
COMBINATION_PRODUCT

Sofosdac®

Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir

Trial Locations (4)

9001

Boufarik Public Hospital, Boufarik

16000

Mustapha Pacha Teaching Hospital, Algiers

31000

Oran Teaching Hospital, Oran

40000

Khenchla Public Hospital, Khenchla

Sponsors

Lead Sponsor

Beker Laboratories
All Listed Sponsors
collaborator

Pharmaceutical Research Unit, Jordan

OTHER

lead

Beker Laboratories

INDUSTRY